Released on 2025-09-10
Longitudinal European Autism Project (LEAP) - Genetics
Accession number
ELU-2-33158B-1
Description
Genetic data derived from human blood and/or saliva samples from LEAP T1 and/or T2.
- Project Title
- AIMS Longitudinal European Autism Project
- Project website
- https://www.aims-2-trials.eu/leap-front-page/
- Version
- 1.0
- Created on
- 2025-06-01
- Updated on
- -
- Experiment types
- Whole genome sequencing Genomics variant array
- Type of Samples Collected
- Whole blood EDTA Whole blood tempus Blood plasma Saliva
- Number of Samples Collected
- 901
- Diseases in samples
- Autism Intellectual disability ADHD (co-occurring)
- Size
- 102 GB
- Dataset file formats
- bed bim fam gz json md pdf tbi tsv txt
- Number of files
- -
- Checksum Algorithm
- -
- Data owner
- -
- Main contact
- Thomas Bourgeron
- thomas.bourgeron@pasteur.fr
- Affiliation
- Institut Pasteur
info Constrained permissions
| Use Condition | Remarks | Category (GA4GH) |
|---|---|---|
| Data can be used in Biomedical and linked research only. | Limited scope of research. Is data consented to be used only in specific research/disease areas? E.g. use only in Biomedical Research. | Other Research-specific restrictions (RS) |
| Approval is provided on a case by case basis by the LEAP Project Review Committee, following submission of a proposal. | User specific restrictions Is the use limited to approved users/groups/institutions? | User-Specific restrictions (US) |
thumb_up Permissions
| Use Condition | Remarks | Category (GA4GH) |
|---|---|---|
| Data can be used outside of the originating project. | Use of DATA is limited to the RESEARCH PROJECT. Is the use of data limited to the project named in the Submission sheet? | Project-Specific restrictions (PS) |
| In accordance with the AIMS-2-TRIALS Data Access Policy, any commercialisation of any Generated IP shall be subject to prior written consent of the Data Provider and, if deemed required, an appropriate revenue sharing agreement will be negotiated between the parties on fair and reasonable terms. Data Users must contact and inform the Data Provider before they intend to commercialse any Generated IP. | Are there any Intellectual Property (IP) restrictions/requirements when using the DATA? | IP claim terms (IP) |
hardware Obligations
| Use Condition | Remarks | Category (GA4GH) |
|---|---|---|
| Acknowledgement of AIMS-LEAP as the source of data, the AIMS funding sources, and the role of ELIXIR Luxembourg is required. Please see LEAP Data Access Policy for more details. | Publication requirements Are there any requirements in case of publications based on the DATA? E.g. papers should cite the cohort study. | Publication Required (PUB) |
| Any results and further derived data obtained from AIMS-LEAP data will be returned to the AIMS-LEAP group, accompanied by all necessary metadata, so as this data would be interpretable by other researchers. These files of research results (which will be clearly marked for provenance) will in turn be available to other researchers who apply for AIMS-LEAP data. The AIMS-LEAP group will not audit these data for quality control: instead the fact that they are available for review by other researchers should result in an effective form of peer review. If such derived data are included within the AIMS-LEAP own database the origin of the data and the means by which they were derived will be clearly flagged. | Data return requirements Is there a requirement to return data or documents to the database/resource? | Return data to database/resource (RTN) |
| The USER INSTITUTION ensures that the DATA USER agrees that his/her personal data (at least his/her name, contact details, title and home institution), information on the RESEARCH PROJECT (comprising its abstract and the PUBLICATIONS) may be posted on the AIMS-2 TRIALS Website. | Other use restrictions (Other) |
